Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?-Reference-Cited by-同舟云学术

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Published:2023-06 Issue: Volume:117 Page:102569
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Corti Chiara,De Angelis Carmine,Bianchini Giampaolo,Malorni Luca,Giuliano Mario,Hamilton Erika,Jeselsohn Rinath,Jhaveri Komal,Curigliano Giuseppe,Criscitiello Carmen

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference81 articles.

1. Gennari A, André F, Barrios C, Cortes J et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology Oct 19, 2021, doi:https://doi.org/10.1016/j.annonc.2021.09.019.

2. Trafficking of nuclear receptors in living cells;Hager;J Steroid Biochem Mol Biol,2000

3. Accelerating drug development in breast cancer: New frontiers for ER inhibition;Ferraro;Cancer Treat Rev,2022

4. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival;Sperduto;Neuro Oncol,2020

5. Ligands specify estrogen receptor alpha nuclear localization and degradation;Kocanova;BMC Cell Biol,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study;Journal of Clinical Oncology;2024-09-06

2. Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER+ breast cancer;Cancer Letters;2024-09

3. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

4. Targeted protein degradation: current molecular targets, localization, and strategies;Drug Discovery Today;2024-09

5. The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?;Annals of Oncology;2024-08